Barclays Boosts Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $55.00

Tandem Diabetes Care (NASDAQ:TNDM - Free Report) had its price target increased by Barclays from $39.00 to $55.00 in a research report sent to investors on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the medical device company's stock.

A number of other brokerages also recently weighed in on TNDM. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a market perform rating to an outperform rating in a research report on Thursday, April 25th. Robert W. Baird increased their target price on Tandem Diabetes Care from $28.00 to $36.00 and gave the stock a neutral rating in a research note on Friday. StockNews.com raised Tandem Diabetes Care from a sell rating to a hold rating in a research note on Friday, April 19th. Citigroup raised their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research note on Wednesday, April 3rd. Finally, Piper Sandler reaffirmed an overweight rating and set a $50.00 price target (up previously from $35.00) on shares of Tandem Diabetes Care in a report on Friday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $43.80.

Tandem Diabetes Care Stock Down 2.7 %

Shares of NASDAQ:TNDM traded down $1.22 during trading on Monday, reaching $43.50. 1,498,367 shares of the company traded hands, compared to its average volume of 1,770,159. The firm has a market cap of $2.81 billion, a P/E ratio of -19.76 and a beta of 1.10. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $47.00. The firm has a fifty day simple moving average of $32.29 and a 200 day simple moving average of $26.19.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. Analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Eminence Capital LP lifted its stake in Tandem Diabetes Care by 76.1% during the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company's stock worth $114,028,000 after purchasing an additional 2,372,458 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Tandem Diabetes Care by 98.1% in the 1st quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company's stock worth $90,512,000 after purchasing an additional 1,265,534 shares in the last quarter. GW&K Investment Management LLC purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter worth $36,288,000. Paradice Investment Management LLC increased its stake in Tandem Diabetes Care by 23.9% in the 3rd quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company's stock worth $31,572,000 after buying an additional 293,250 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of Tandem Diabetes Care in the 1st quarter valued at about $8,018,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.